original ) (raw )Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer
francisco salvador gomez
The Prostate, 2013
View PDFchevron_right
Dual EGFR/HER2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Withdrawal by Suppressing ErbB3
Elyse van Spyk
Clinical Cancer Research, 2011
View PDFchevron_right
Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7
Masaki Shiota
Journal of the National Cancer Institute, 2016
View PDFchevron_right
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
Dean Tang
Nature communications, 2018
View PDFchevron_right
HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway
Mickey Hu
Cancer research, 2000
View PDFchevron_right
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
Walther Parson
Oncotarget, 2014
View PDFchevron_right
Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands
Clara Panosa
International Journal of Oncology, 2012
View PDFchevron_right
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines
Yingming Li
2013
View PDFchevron_right
A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer
Derek J Rosario
Cancer Management and Research, 2015
View PDFchevron_right
Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer
Cora Sternberg
Future Oncology, 2019
View PDFchevron_right
Androgen-Dependent Regulation of Her-2/neu in Prostate Cancer Cells
Raanan Berger
Cancer Research, 2006
View PDFchevron_right
Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer
Daniela Schuster
2020
View PDFchevron_right
Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
Marcello Tucci
OncoTargets and Therapy, 2018
View PDFchevron_right
NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants
Ramakumar Tummala
Molecular cancer therapeutics, 2013
View PDFchevron_right
PCA3 Silencing Sensitizes Prostate Cancer Cells to Enzalutamide-mediated Androgen Receptor Blockade
Ugur Gezer
Anticancer Research, 2017
View PDFchevron_right
Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer
Akira Yokomizo
The Prostate, 2014
View PDFchevron_right
Targeting androgen receptor activation function-1 with EPI to overcome resistance mechanisms in castration-resistant prostate cancer
Iain McEwan
Clinical cancer research : an official journal of the American Association for Cancer Research, 2016
View PDFchevron_right
Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer
Anh Khoi Hoang
European Urology, 2015
View PDFchevron_right
Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models
Barry Davies
European Urology, 2014
View PDFchevron_right
Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer
Rupert Fray
Frontiers in Endocrinology
View PDFchevron_right
Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer
scott lawrence
Nature Chemical Biology, 2016
View PDFchevron_right
Regulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3′-diindolylmethane in an enzalutamide-resistant prostate cancer cell line
Chih-Wei Tsao
Scientific Reports, 2021
View PDFchevron_right
Enzalutamide: A new prostate cancer targeted therapy against the androgen receptor
lucia santome
Cancer Treatment Reviews, 2015
View PDFchevron_right
Elevated levels of HER-2/ neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential
Carmela Ricciardelli
The Prostate, 2008
View PDFchevron_right
Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
Asish Pati
Frontiers in Oncology, 2020
View PDFchevron_right
From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
Hong-yo Kang , Hsiang-wen Lin
Proceedings of the National Academy of Sciences, 1999
View PDFchevron_right
AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells
Phumvadee Wangtrakuldee
Molecular Cancer Therapeutics, 2018
View PDFchevron_right
Targeting HER2 in Prostate Cancer: Where to Next?
Neal Rosen
Journal of Clinical Oncology, 2007
View PDFchevron_right
Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer
johnny silva
Cancer research, 2002
View PDFchevron_right